Status:
COMPLETED
Effect of Different Dosing Regimens of Clopidogrel Before Elective Percutaneous Coronary Intervention (PCI) on Platelet Function
Lead Sponsor:
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-90 years
Phase:
PHASE3
Brief Summary
Adequate platelet inhibition before percutaneous coronary intervention (PCI) reduces peri-procedural and long-term ischemic complications. Documented reduced response to clopidogrel has been associate...
Eligibility Criteria
Inclusion
- Adult patient with an indication for elective coronary angiography with or without PCI
Exclusion
- major hemorrhagic diathesis or active bleeding
- acute myocardial infarction (MI) within 14 days of enrolment
- unstable angina with ST-segment changes \>1 mm in at least two contiguous electrocardiographic leads at rest or a troponin I level \>0.06 microg/L within 14 days of enrolment
- stroke within the past 3 months
- platelet count \<100 x 10 9/L
- prothrombin time \> 1.5 times control
- hematocrit \<25% or hemoglobin level \<100 g/L
- alcohol or drug abuse
- enrolment in other investigational drug trials within the previous month
- use of thienopyridines, glycoprotein (GP) IIb/IIIa inhibitors, warfarin or acenocoumarol within the previous week
- allergic reaction or any contraindication to clopidogrel or aspirin administration
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2006
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00693069
Start Date
September 1 2004
End Date
April 1 2006
Last Update
August 21 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital du Sacre-Coeur de Montreal
Montreal, Quebec, Canada, H4J 1C5